Treatment of corticosteroid-resistant ulcerative colitis with oral low molecular weight heparin

Table 1 Therapeutic effects of oral LMWH in corticosteroid-resist ant UC patients

Group	Stool frequency (times/day)	Rectal bleeding (score)	Colonoscopy (score)	Histology (score)	Well-being (score)
Pre-treatment	8.6	2.6	2.7	12.0	4.0
Post-treatment	1.5b	0.2b	1.0b	4.0b	0.6b

^bP < 0.01 vs pretr eatment.

Table 2 Effects of oral LMWH on CD_62P and CD₆₃, TXA₂, platelet aggregation rate (PAR) and thrombosis length (TL) in vitro in UC patients (x^-± s)

Group	CD62P (%)	CD63 (%)	TXA2 (ng/L)	PAR (%)	TL (cm)
UC patients
Pre-treatment	8.1 ± 3.2b	6.2 ± 2.2b	541.7 ± 82.4b	44.5 ± 10.1b	2.4 ± 0.5b
Post-treatment	4.2 ± 1.9ad	3.1 ± 1.7ab	396.4 ± 75.8d	35.2 ± 8.7d	1.9 ± 0.4d
Normal controls	1.9 ± 00.4	1.6 ± 0.8	340.2 ± 40.4	34.1 ± 9.1

^aP < 0.05,

^bP < 0.01 vs normal person;

^dP < 0.01 vs pretreatment.

Table 3 Effects of oral LMWH on CD₅₄ in UC patients (x^-± s, %)

Group	Blood CD54	Tissue CD54
UC patients
Pre-treatment	28.7 ± 6.1b	50.7 ± 6.8b
Post-treatment	14.6 ± 5.2ad	22.8 ± 4.7ad
Normal controls	6.2 ± 3.7	8.8 ± 3.2

^aP < 0.05,

^bP < 0.01 vs normal;

^dP < 0.01 vs post-treatment.